BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26899763)

  • 21. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
    Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.
    Lal P; Tan LK; Chen B
    Am J Clin Pathol; 2005 Apr; 123(4):541-6. PubMed ID: 15743737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site.
    Koo JS; Jung W; Jeong J
    Tumori; 2010; 96(3):424-32. PubMed ID: 20845803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
    Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
    Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
    Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
    [No Abstract]   [Full Text] [Related]  

  • 26. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
    Yao ZX; Lu LJ; Wang RJ; Jin LB; Liu SC; Li HY; Ren GS; Wu KN; Wang DL; Kong LQ
    Med Oncol; 2014 Jan; 31(1):798. PubMed ID: 24307349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Could the Breast Prognostic Biomarker Status Change During Disease Progression? An Immunohistochemical Comparison between Primary Tumors and Synchronous Nodal Metastasis.
    El Nemr Esmail RS; El Farouk Abdel-Salam LO; Abd El Ellah MM
    Asian Pac J Cancer Prev; 2015; 16(10):4317-21. PubMed ID: 26028092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
    Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
    Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
    Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion of hormone and HER-2 receptor in metachronous neck metastases from breast carcinoma.
    Nauroth A; Kalder M; Rössler M; Wichmann G; Dietz A; Wiegand S
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1811-1814. PubMed ID: 28429100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.
    Aitken SJ; Thomas JS; Langdon SP; Harrison DJ; Faratian D
    Ann Oncol; 2010 Jun; 21(6):1254-1261. PubMed ID: 19858088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated With Node-Positive Disease in Estrogen Receptor-Positive Breast Cancer Patients.
    Gallagher J; Elleson KM; Englander K; Chintapally N; Sun W; Whiting J; Laronga C; Lee MC
    J Surg Res; 2024 Mar; 295():327-331. PubMed ID: 38061237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
    East EG; Pang JC; Kidwell KM; Jorns JM
    Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of EDTA decalcification on estrogen receptor and progesterone receptor immunohistochemistry and HER2/neu fluorescence in situ hybridization in breast carcinoma.
    Washburn E; Tang X; Caruso C; Walls M; Han B
    Hum Pathol; 2021 Nov; 117():108-114. PubMed ID: 34461131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.
    Walter V; Fischer C; Deutsch TM; Ersing C; Nees J; Schütz F; Fremd C; Grischke EM; Sinn P; Brucker SY; Schneeweiss A; Hartkopf AD; Wallwiener M
    Breast Cancer Res Treat; 2020 Aug; 183(1):137-144. PubMed ID: 32613540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases.
    Zhao J; Hu C; Wang C; Yu W; Guo Y; Shi M; Shui Y; Wei Q
    BMC Cancer; 2018 Dec; 18(1):1290. PubMed ID: 30587150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status.
    Vellaisamy G; Tirumalae R; Inchara YK
    J Cancer Res Ther; 2019; 15(5):989-993. PubMed ID: 31603099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.